Safety and efficacy of cyclooxygenase-2 inhibition for treatment of primary hypertrophic osteoarthropathy: A single-arm intervention trial

BACKGROUND: Primary hypertrophic osteoarthropathy (PHO) is a rare disease involving joint, bone and skin. Two underlying genes responsible for this disease—hydroxyprostaglandin dehydrogenase (HPGD) and solute carrier organic anion transporter family, member 2A1 (SLCO2A1)—are both associated with abe...

Descripción completa

Detalles Bibliográficos
Autores principales: Yuan, Lu, Liao, Ruo-xi, Lin, Yuan-yuan, Jiang, Yan, Wang, Ou, Li, Mei, Xing, Xiao-ping, Pang, Qian-qian, Hsieh, Evelyn, Xia, Wei-bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Chinese Speaking Orthopaedic Society 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718875/
https://www.ncbi.nlm.nih.gov/pubmed/31508314
http://dx.doi.org/10.1016/j.jot.2018.10.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718875/
https://www.ncbi.nlm.nih.gov/pubmed/31508314
http://dx.doi.org/10.1016/j.jot.2018.10.001

Ejemplares similares